BridgeBio reported positive Phase III results for encaleret in autosomal dominant hypocalcemia type 1 (ADH1), meeting primary and key secondary endpoints with a high proportion of patients achieving serum and urine calcium targets at 24 weeks. The company said the oral therapy was generally well tolerated and plans a regulatory filing next year. The success adds momentum to BridgeBio’s portfolio after recent late-stage wins and could establish encaleret as a new standard for this rare endocrine disorder. Investors and rare-disease clinicians will track regulatory submission timing and labeling discussions, particularly around long-term safety and real-world management without supplemental calcium. BridgeBio’s outcome also signals continued investor appetite for rare-disease late-stage assets with clear biomarker-driven endpoints, and sets expectations for other sponsors with similarly designed registrational programs.